Amyotrophic lateral sclerosis (ALS) was first described 134 years ago. While still incurable, significant progress has been made in understanding the pathophysiology of the disease and its management. For example, it is now clear that ALS is not a single disease; there are familial and sporadic subtypes. ALS is not specific for motor neurons; other cell types are involved and in fact may be critical in determining disease progression. A number of options now exist for managing the troublesome symptoms of ALS, and we have a pipeline of potential ALS therapeutics, which is larger and more varied than ever before. Finally, we are on the cusp of a diagnostic test for ALS that will allow us to get these therapies to patients more quickly. 
OVERVIEW
Amyotrophic lateral sclerosis (ALS) was first described by Jean Martin Charcot in 1874, and his description of the disease remains quite accurate today. ALS typically involves widespread degeneration of upper and lower motor neurons. As lower motor neurons degenerate, patients with ALS manifest lower motor neuron signs, such as muscle atrophy, fasciculations, and weakness (Charcot's term for these was amyotrophy). As upper motor neurons degenerate (and ''lateral sclerosis'' in the spinal cord ensues), patients with ALS manifest upper motor neuron signs, including spastic tone, hyperreflexia, and Babinski sign. These signs relentlessly spread within and then across multiple spinal segments, including the lumbosacral, thoracic, cervical, and bulbar segments. Over the course of their disease, most patients with ALS will lose their ability to control their limbs, to speak, to swallow, and to breathe. Without mechanical ventilation, death from respiratory failure typically ensues within 3 to 5 years of symptom onset.
In the years since Charcot's initial description, progress has been made in the understanding of the pathophysiology of ALS and treatment of its symptoms. This chapter will focus on the progress that has been made over the past decade in our understanding of the pathomechanisms of ALS and will also review current concepts of diagnosis and management. As will be described in greater detail, work in this brief time period has yielded dramatic changes in our concept of ALS. Advances in molecular biology have allowed characterization of 14 familial ALS (FALS) subtypes and identified potential susceptibility genes that may interact with environmental triggers to initiate subtypes of sporadic ALS (SALS). Gains in our understanding of downstream ALS pathophysiology have led to the current belief that nonneuronal cells are not only affected by ALS but may also be important determinants of ALS progression. Within FALS type 1 (FALS1), the role of mutant superoxide dismutase 1 (mSOD1) protein is becoming clearer, including identification of specific intracellular binding sites that may be critical for how this protein produces disease. Similarities and important differences between FALS1 and the much more common SALS pathophysiology are being elucidated, including a possible key difference in the processing of another protein called TDP43. The combination of many new therapeutic targets, earlier diagnosis, new technologies such as gene and stem cell therapy, and increasing knowledge of potential pitfalls in preclinical and clinical ALS trial design warrant optimism in the ongoing search for better disease-modifying treatments. In the meantime, symptomatic treatment continues to improve.
A NEW CONCEPT OF ALS
One Disease or Many? Clinical and laboratory differences among patients with ALS have long raised questions about whether this is one disease or many related ones. The typical age of ALS onset is 60 years; however, the range is anywhere from the teenage years to the 90s. Weakness begins in a distal extremity muscle in most patients, but about one-third have a bulbar onset. Progression from symptom onset to death or tracheostomy ranges from months to many decades. Some patients with ALS have comorbid frontotemporal dementia. Some patients with ALS have a strong family history (familial ALS [FALS] ), while at least 90% have none (SALS). In recent years, 14 different genes have been identified that can cause various types of motor neuron disease. Very recent studies looking for genetic susceptibility and environmental exposures that might underlie SALS find more differences across populations than similarities. Finally, downstream mechanistic events that are evident in some forms of ALS do not appear to be as obvious in others. The best evidence for this involves the very recent detection of a protein TDP-43 in the ubiquinated intraneuronal cytoplasmic protein aggregates of SALS and some forms of FALS; TDP-43 is either not present or is more difficult to find in these aggregates in FALS1.
Not Just Motor
Neurons Anymore ALS has long been considered a degenerative disease specific for motor neurons. In the time since Charcot's first report, patients with ALS have been described as manifesting problems with other neuronal cell types; sensory dysfunction, autonomic dysfunction, parkinsonism, dementia, and behavioral disturbances have all been reported. Until recently, though, involvement of these other neuronal populations was considered to be very rare. Over the past few years, a number of investigators have performed detailed neuropsychiatric testing on small groups of consecutive patients with ALS presenting to their clinics. The surprising and reproducible finding from these small studies is that the frequency of dementia and more subtle cognitive and behavioral disorders is much higher than predicted. In a 2007 study, for example, 22% of consecutive patients with ALS met Neary criteria for frontotemporal dementia; another 17% had behavior disturbances, including irritability and disinhibition; and another 10% had subtle cognitive problems with higher executive tasks (Murphy et al, 2007) . Recognition of these comorbidities, even when subtle, is probably important in developing strategies for helping patients and their families navigate through an increasing number of complex options for management of their disease.
Perhaps even more surprising, recent studies suggest that non-neuronal cells are affected in ALS and may indeed be critical for disease progression; events occurring within motor neurons now appear to determine disease onset, while events occurring within glial cells appear to determine progression rate.
ADVANCES IN PATHOGENESIS

Initiation of Familial ALS
The two broad categories of ALS, FALS and SALS, are distinguished by their cause or initiating events. FALS accounts for 3% to 10% of all ALS. Patients with FALS usually have a strong family history of ALS and have a diseasecausing genetic mutation. At the time of this writing, mutations in 14 different genes have been described as causing FALS (Table 4-1). Most often, these have autosomal dominant inheritance, but recessive and even X-linked inheritance has been described. While some FALS mutations (such as FALS1, FALS3, FALS6, FALS7, and FALS-ANG) cause a phenotype indistinguishable from typical SALS, others look quite different. For example, FALS2, FALS4, and FALS5 mutations cause childhood-onset motor neuron disease with slow progression. FALS-FTDP causes amyotrophy with frontotemporal dementia and parkinsonism. Further complicating matters, different mutations within the same FALS gene can cause very different phenotypes. For example, within FALS1, an A4V mutation in SOD1 typically results in a predominantly lower motor neuron disease with rapid progression and a mean survival of approximately 1 year. In contrast, an H46R mutation in the same gene causes a predominantly lower motor neuron disease with much longer survival, up to more than 40 years. Phenotypic variability across different mutations in the same FALS gene may stem from differences in the stability of the resultant protein product. Finally, the exact same mutation in the same FALS gene can result in different phenotypes, apparently as the result of modifier genes. In FALS1 with a V148G mutation in SOD1, for example, the phenotype depends on the CNTF gene. Patients who have at least one copy of CNTF have a late-onset form of FALS, with typical progression rate, whereas those with a null mutation in CNTF have an early-onset, more rapidly progressive form of FALS (Andersen, 2006) .
Most of the FALS mutations are very rare; indeed, many are only described in single families. Even FALS1, the most common of these, accounts for only about 2% to 3% of all ALS. Nonetheless, FALS is important for at least three reasons: (1) The study of these mutations has shed important light on potential upstream processes that may be relevant in SALS and on processes that may contribute to the progression of SALS. (2) The commercial availability of FALS genetic testing has given us a potential diagnostic test for ALS. (3) FALS mutations can now be inserted into a variety of animals, giving us valuable models for studying ALS mechanisms and screening potential disease-modifying agents. The most studied of these is the SOD1-mutant mouse (Julien and Kriz, 2006 It is important to note that none of these are perfect models of any type of ALS. Their motor systems are organized differently, and as a result, their upper motor neuron signs are not as obvious. They also have multiple copies of mutant SOD1, rather than a single one as humans do. These differences may be part of the reason that multiple therapies work to prolong survival in mSOD1 mice, yet only one of these, riluzole, has ever worked in humans with SALS. (Schymick et al, 2007; Siddique, 2008) . The most recent of these studies has proposed haploinsufficiency, or an excess of deleted genes, as a susceptibility factor in SALS (Blauw et al, 2008) . Unfortunately, since the overall number of deletions and duplications did not differ between patients with ALS and controls in this study, the detected aggregation of heterozygous deletions in genes may simply be a random process (Siddique, 2008) . As with susceptibility genes, the search for environmental triggers for ALS has thus far yielded interesting but confusing results (Nelson and McGuire, 2006) . Two major methods have been employed: cluster studies and casecontrol studies. Cluster studies rely on the fact that ALS is a rare disease throughout most of the world. This point can be debated; after all, the incidence of 1 to 2 per 100,000 per year makes it is as common as multiple sclerosis, and the lifetime risk of developing ALS is around 1 in 400. Nonetheless, the relative rarity of ALS makes clusters of disease easier to spot. The most famous geographic ALS cluster occurred on the island of Guam, in which a native population called the Chamorro once had a 50-fold to 100-fold increase in ALS incidence. Over time, this has significantly improved. Controversy still exists over the trigger for Guamanian ALS, with leading theories including consumption of neurotoxincontaining cycad seeds, consumption of neurotoxin-containing fruit bats, exposure to neurotoxin-producing cyanobacteria (Cox et al, 2008) , and transmission of familial susceptibility genes (Steele and McGeer, 2008 (Edwards et al, 2007) ; this has yet to be replicated using more traditional methodology. Some small case-control studies have suggested that patients with ALS may be more likely to have been exposed to metals, solvents, pesticides, and electric shocks and may be more likely to have smoked cigarettes and to have been athletic (Nelson and McGuire, 2006) . Unfortunately, none of these potential environmental triggers is consistently found across case-control studies. The National Registry of Veterans with ALS, which currently includes more than 2300 confirmed cases (Allen et al, 2008) , and the proposed US National ALS Registry, which could have more than 10 times this number, should be helpful in identifying new clusters and carrying out more powerful case-control studies. phenotype (Andersen, 2006) . Exactly what the pathologic function of mSOD1 is remains a mystery, but its ability to form aggregates appears important. Intraneuronal, ubiquinated cytoplasmic protein aggregates are a pathologic hallmark of FALS. These aggregates appear unique to motor neurons and surrounding astrocytes in FALS models; in FALS1 culture models, for example, hippocampal and dorsal root ganglia neurons are spared from aggregates and degeneration. In FALS1 animals, aggregation appears to occur temporally prior to any other measure of FALS1 phenotype. In animals and humans with FALS1, a correlation exists between the stability of mSOD1 protein and disease progression; mutations coding for the most unstable protein are associated with the fastest progression. Treatment of FALS1 models with agents that impair mSOD1 aggregation is associated with prolonged survival (Kieran et al, 2004) . Aggregates of mSOD1 may create loss of other important proteins, such as the antiapoptotic protein Bcl-2, via coaggregation and may overwhelm the processing of other proteins, such as neurofilaments and peripherin, through the normal chaperone or ubiquitin-proteosome machinery.
Initiation of Sporadic ALS
Specific mSOD1 binding sites have recently been elucidated (Polymenidou and Cleveland, 2008) (Table 4 -3). Misfolded mSOD1 protein binds to the outer mitochondrial membrane of FALS1 animal spinal cord neurons. This binding may be responsible, in turn, for the morphologic abnormalities seen in FALS1 animal mitochondria, which temporally correlate with the onset of weakness, and for impairments in mitochondrial energy production and leakage of mitochondrial cytochrome c into the cytoplasm where it is a potent trigger for apoptosis (Manfredi and Beal, 2006) . The mSOD1 protein can bind to the dynein/dynactin motor complex and in doing so may be responsible for the impairments in axonal transport seen in FALS1 models; indeed, a second mutation in the dynein/dynactin complex, which impairs this mSOD1 binding, can prolong survival in FALS1 models (Zhang et al, 2007) . In the past year, the mSOD1 protein has been shown to bind to two other targets in FALS1 models: Rac1 and Derlin-1. When mSOD1 binds to Rac1, the resulting complex appears to lock nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) into its active, superoxide-generating form, resulting in a 10-fold increase in superoxide production. The blocking of this interaction in FALS1 mice results in an increase in survival. When mSOD1 binds to Derlin-1, the endoplasmic reticulumassociated degradation (ERAD) system for eliminating misfolded proteins via the endoplasmic reticulum is impaired, and the proapoptotic kinase Ask-1 is activated. Deletion of the Ask-1 gene prolongs survival in FALS1 mice (Polymenidou and Cleveland, 2008) .
As mentioned earlier, it is now clear that glial cells play an important downstream role in FALS1 mice. Experiments in 2001 and 2002 showed that selective expression of mSOD1 in mouse motor neurons alone was not enough to produce an ALS phenotype. A study of chimeric mice in 2003 showed that pockets of motor neurons could survive in the spinal cord, even if they were full of mSOD1, as long as they were surrounded by wild-type glial cells. Cell culture studies in 2007 confirmed and extended the chimeric study. Again, mSOD1 motor neurons were shown to prosper when cocultured with wild-type astrocytes, but wild-type motor neurons did not survive when co-cultured with mSOD1 astrocytes. Finally, selective deletion of mSOD1 in the motor neurons of FALS1 mice delayed disease onset but had no effect on progression. hand, selective deletion of mSOD1 in microglia had no effect on disease onset but significantly delayed disease progression (Boillée et al, 2006) .
Specific mechanisms by which glial cells participate in FALS1 pathophysiology are emerging ( Cleveland, 2008). This may explain the finding of increased extracellular glutamate levels in FALS models. Inducing a loss of EAAT2/GLT1 via antisense oligonucleotides can induce motor neuron degeneration in cell culture and animal models. Crossbreeding mutant SOD1 mice with mice that overexpress EAAT2/GLT1 delays FALS1 onset. The antibiotic ceftriaxone increases EAAT2/ GLT1 messenger RNA and protein levels and prolongs survival in FALS1 models (Rothstein et al, 2005) .
Downstream Events:
Sporadic ALS Many of the downstream events discovered in FALS1 models are being found to be relevant in patients with SALS as well. Intracytoplasmic protein aggregates are found in the motor neurons of patients with SALS. Many of the proteins in these aggregates overlap with those found in FALS1 aggregates, including neurofilaments and peripherin. Mitochondrial abnormalities occur in patients with SALS. Specifically, mitochondrial morphology is abnormal in SALS motor neurons; SALS mitochondria have abnormally elevated intracellular calcium, and they have defects in respiratory chain activities (Manfredi and Beal, 2006) . Excitotoxicity appears to be active in SALS.
Patients with SALS have elevated CSF glutamate levels, and their CSF is toxic to motor neurons in cultures. As seen in animals and patients with FALS1, loss of EAAT2/GLT1 occurs in patients with SALS (Rothstein et al, 2005) and may be the reason for the elevated CSF glutamate. The immune system is not functioning normally in patients with SALS. Microglia are widely active throughout the brain, and cyclooxygenase-2 (COX-2) activity is increased in the spinal cord of patients with SALS. Increased markers of oxidative stress have been found in patients with SALS (Barber et al, 2006) . Axonal transport is abnormal in patients with SALS. Anterograde trafficking of organelles is significantly increased, while retrograde trafficking is slowed (Grierson and Miller, 2006) . Finally, apoptosis is likely an important downstream pathway in SALS. Evidence for this comes from histologic and immunohistochemical studies on spinal cord sections that demonstrate shrunken cells with small Nissl-positive bodies, fragmented DNA, overexpression of proapoptotic Bax mRNA and underexpression of antiapoptotic Bcl-2 messenger RNA (mRNA), increased expression of the prodeath molecule Harakiri, appearance of apoptosis-specific Le(y) antibodies, elevated CDK5 immunoreactivity, increased amounts of caspases 1 and 9 in CSF, and increased expression of PAR-4 and p53 in motor cortex and spinal cord tissue. Interestingly, overactivation of the proapoptotic c-Jun-JNK/SAPK pathway also occurs specifically within SALS spinal cord astrocytes (Pasinelli and Brown, 2006) . While these similarities are encouraging, recent work with TAR DNA binding protein-43 (TDP-43) raises the possibility that there are important differences in downstream FALS1 and SALS mechanisms. In 2006, TDP-43 was found to be one of the major proteins in the intracytoplasmic aggregates found in SALS, in many types of FALS, and in frontotemporal dementia. Subsequently, this protein has been found in the aggregates of Alzheimer disease, Pick disease, and Lewy body dementia. However, TDP-43 is either not present or is much harder to find in the ubiquinated aggregates of animal models or patients with FALS1. The relevance of this is unclear, but increasing data suggest that TDP-43 may be playing a critical role in motor neuron disease pathogenesis. For example, in addition to being sequestered in aggregates, TDP-43 is depleted from the nucleus in these conditions. In 2008, disease-causing TDP-43 mutations were found in rare patients with FALS and SALS. TDP-43's potential roles in ALS include transcriptional repression, activation of exon skipping, mRNA biogenesis, apoptosis, and cell division. If TDP-43 does turn out to be important in ALS pathogenesis, its absence or decrease in FALS1 would suggest a key difference between this best understood form of ALS and the other forms, including SALS (Banks et al, 2008) .
DIAGNOSIS
Elucidation of the pathophysiologies of ALS, along with new drug discovery techniques, is resulting in a rich pipeline of potential disease-modifying therapies for ALS trials. Unfortunately, the current method for diagnosing ALS is likely to limit the success of these trials. This method is largely unchanged from the time of Charcot. ALS continues to be diagnosed and followed almost entirely on the basis of clinical findingsthe history and the neurologic examination. A clinical diagnosis of ALS requires the presence of progressive upper and lower motor neuron signs, spanning multiple spinal segments, with no other possible explanation. As more spinal segments become involved, diagnostic certainty increases. The El Escorial criteria (Table 4-4) take the number of segments into account in assigning a diagnostic certainty level; these are most useful for selecting trial subjects. Autopsy studies confirm that, while very specific, this method may miss cases of ALS. For example, more than half the patients thought to have a pure lower motor neuron disease in life (progressive muscular atrophy) actually had classic ALS at autopsy. Additionally, the interval between a patient's initial symptoms and a diagnosis of ALS is believed to be approximately 15 months. In this interval, it has been estimated that approximately half the motor neuron pool is lost. This diagnostic delay is a daunting problem for the development of disease-modifying therapies; indeed, FALS1 animal studies confirm that earlier treatment is often Case 4-1, Part 1
An otherwise healthy 45-year-old male veteran presented with a report of weakness. One year ago, he noted a right-sided limp when running. Over time, he developed an obvious right footdrop. He could not climb stairs as well as he used to, and he started to have difficulty opening jars using his right hand. It became harder for him to operate his farming equipment. These symptoms were accompanied by muscle shrinkage, twitching, and cramps, but not by pain, sensory loss, ocular, bowel, or bladder dysfunction. Initial outside workup included a lumbar MRI, which showed a disk bulge. He underwent back surgery for the disk bulge, but it was not helpful. His local physician eventually noted atrophy in the right leg and hand and suspected a neuromuscular disease, prompting referral. Past medical history was unremarkable. The patient took no medications. He smoked but used no recreational drugs. He had no HIV risk factors. His family history was negative, but he did not know all the relatives on his father's side. He was married with two small children. Review of systems was notable for difficulty controlling his laughing and crying. He denied depression. He had experienced a 9.1-kg weight loss over the past year. On examination, he was thin and athletic. He exhibited pathologic laughing and crying. His forced vital capacity (FVC) was 78% of predicted. He was alert and oriented without dysarthria or aphasia. Mini-Mental State Examination score was 30/30. Motor examination revealed atrophy of his entire right leg and the ulnar and median intrinsic muscles of the right hand. He had diffuse fasciculations in all limbs. Tone was increased in the right leg. The right median and ulnar myotomes were weak at 4/5. Both lower extremities were weak, right worse than left, distal worse than proximal. His right ankle dorsiflexor strength was less than antigravity. Sensory examination was unremarkable. Reflexes were pathologically brisk in the arms and legs with Hoffman and Babinski signs present. Workup included nerve conduction studies and EMG, which demonstrated a motor axonopathy affecting multiple cervical, midthoracic, and lumbosacral myotomes. SOD1 genetic testing was negative. ALS mimic testing, including Lyme enzyme-linked immunosorbent assay, serum copper, paraneoplastic antibodies, and CT scan of the chest, abdomen, and pelvis, was unremarkable. The patient's condition was diagnosed as clinically probable ALS by El Escorial criteria.
Comment. This patient's history and examination demonstrated a progressive upper and lower motor neuron disease affecting the cervical and lumbosacral segments. EMG confirmed the lower motor neuron component of this and demonstrated subclinical involvement of the thoracic segment as well. He thus meets El Escorial criteria for clinically probable ALS. There is a limited differential diagnosis (see the chapter ''Clinical Spectrum of Motor Neuron Disorders'') for this localization, which may include infections such as Lyme, HIV, human T-lymphotropic virus types 1 and 2, syphilis (he had no risk factors for the latter three), copper deficiency, and paraneoplastic syndrome. Even these are controversial and supported only by rare case reports in the literature. The interval between his first symptoms and his diagnosis was over a year, and he underwent an unnecessary surgery en route to his diagnosis; these are common problems and illustrate the need for better ALS diagnostic methods. He has no definite family history of ALS and no SOD1 mutation; thus he appears to have sporadic ALS. Potential risk factors for his disease include his military service and exposure to insecticides and herbicides on his farm.
category of laboratory-supported probable ALS in which upper and lower motor neuron signs are present in a single spinal segment, and also denervation on EMG in more than one region (Table 4-4). Most trials now allow patients in this category to participate. A variety of other techniques have been suggested to improve the detection of upper motor neuron signs, including magnetic resonance spectroscopy (MRS) and transcranial magnetic stimulation (TMS). Using MRS, recent studies have described a decrease in the ratio of N-acetylaspartate to creatinine in the motor cortex of patients with ALS and slowing of central motor conduction times in patients with ALS. One study tested both MRS and TMS, with examination findings as the criterion standard. MRS had a sensitivity of 0.86 and specificity of 0.77; TMS had a sensitivity of 0.77 and specificity of 0.38 (Kaufmann et al, 2004) . While these data are interesting, improved sensitivity and specificity, cost, and availability will probably be necessary before they gain widespread use as diagnostic tools.
In 2006, a very interesting study was published, identifying a potential CSF test for ALS (Pasinetti et al, 2006) . This study utilized a technique called surface-enhanced laser desorption ionization mass spectrometry (SELDI-MS), which allows comparison of thousands of proteins in body fluid across different populations. In the discovery part of this study, the technique was used to look for differences in proteins in a sample of 36 patients with ALS versus 21 healthy controls. Significant differences were found in three proteins: patients with ALS had lower amounts of cystatin C, VGF, and an unidentified 6.7 Kda protein. In the validation part of this study, the identified differences in protein were used, either alone or together, to try to separate 13 patients with ALS from 25 healthy controls, 18 patients with Parkinson disease, and 7 patients with neuropathy. Using just a single protein, the diagnostic accuracy (percentage correctly classified as having ALS or not) ranged from 65% to 88%. However, when differences in all three proteins were used together as a diagnostic fingerprint of ALS, the accuracy was 95%. Validation and extension of this very important study is currently underway across North America.
MANAGEMENT Overview
A patient with ALS goes through various phases, including adapting to the diagnosis, coping with increasing functional impairment and disability, and dealing with end-of-life issues. The phase after death is important for the needs of the family and caregivers. In recent years, small studies and practice parameters based on the opinion of clinicians with many years of experience with ALS have outlined a variety of options for every phase of ALS care (Andersen et al, 2007; Miller et al, 1999; Radunović et al, 2007) . It is important to remember that these are treatment options; all patients' autonomy should be respected as they choose which of these options they will accept.
Breaking the News
Guidelines for communicating the diagnosis have now been established. The diagnosis should be made according to well-established criteria. The physician should give the diagnosis to the patient and family in person and discuss its implications: that there is no cure, and symptoms tend to worsen steadily. It is important to stress that prognosis is highly variable; long-term survival is possible although difficult to predict. Patients and family members should be reassured that the patient will continue to be cared for, and contact information for the team and local support groups should be provided. The benefits of multidisciplinary care and the hope offered by ongoing research should be stressed.
Specialist Multidisciplinary Approach
The single greatest advance in the management of patients with ALS has been the formation of clinics with specialized multidisciplinary teams. Multiple studies have shown that attendance at a specialist multidisciplinary ALS clinic may prolong survival and improve the quality of life of patients with ALS. In a population-based study in Ireland, Traynor and colleagues (2003) showed that patients with ALS who attended a multidisciplinary ALS clinic lived an average of 7.5 months longer than individuals who received their medical care at a general neurology clinic. One-year mortality was reduced by nearly 30%, which is comparable to the reduction in 1-year mortality observed with riluzole in clinical trials (38.6%). In another study, Chiò and colleagues (2006) also observed longer median survival time (1080 versus 775 days) for patients with ALS followed up by tertiary ALS centers, even when stratifying by age, site of onset, and respiratory function at diagnosis. In Cox multivariate analysis, attending a tertiary ALS center was observed to be an independent positive prognostic factor. Moreover, patients attending a tertiary ALS center had fewer unplanned hospitalizations. In a crosssectional study, patients in the multidisciplinary ALS care group had a better mental quality of life on the SF-36 (36-item short form health survey) mental summary score than those in the general care group (P = .01).
The difference in quality of life was most pronounced in the domains of social functioning and mental health (Van den Berg et al, 2005) . In addition, the percentage of patients with adequate aids and appliances was higher in those receiving multidisciplinary care, particularly if patients had problems communicating or swallowing.
Modern multidisciplinary teams have evolved to comprise several team members, each of whom sees every patient every time the patient comes to the clinic (on average about every 3 months). These teams usually include a neurologist with an interest in ALS who breaks the news, performs periodic histories and examinations, prescribes medication and equipment, coordinates the recommendations of the other team members, answers medical and scientific questions, and advocates for participation in research. Most teams have a nurse clinician who extends the role of the neurologist in addressing medical questions and concerns. The nurse clinician also provides teaching, reviews various skills on an on-going basis, and liaises with community organizations. In many clinics, the nurse clinician is also involved in the research studies. The team speech-language pathologist helps evaluate oral motor function, cognitivelinguistic function, augmentative communication function, and swallowing function and provides advice on techniques and strategies to allow people with ALS to communicate throughout life. The nutritionist performs weight measurements, body mass index, and calorie counts. Working together with the speech pathologist, the nutritionist recommends a specific diet to stabilize weight in the interval between visits. The occupational therapist assesses driving ability, access to various rooms in the home, and performance of activities of daily living, whereas the physical therapist assesses gait, transfers, and a home exercise program; these two work together to suggest behavior modifications and equipment to maximize function and safety at various points throughout the disease process. A respiratory therapist measures pulmonary function, assists with teaching breath stacking and hyperinflation, and outlines equipment options such as suction, cough assist devices, bilevel positive airway pressure (BiPAP) device, and mechanical ventilation. A neuropsychologist may help the neurologist screen for subtle cognitive and behavioral abnormalities that might impair decision making, screens for depression and anxiety, and helps plan the treatment of these conditions when detected. The clinic social worker provides disease education, emotional support, a liaison to support groups and other community resources, and information on living wills and health care power of attorney. A research coordinator supplements information provided by the neurologist about research options and coordinates the research projects themselves. These clinics are expensive to create and maintain. The ALS Association and Muscular Dystrophy Association provide indispensable financial support for these clinics in the United States. Despite the positive effect of multidisciplinary care, current data suggest that only 45% of patients with ALS ever set foot in a multidisciplinary clinic (Khischenko and Bedlack, unpublished data from the National Registry of Veterans with ALS, 2007).
Palliative Care
As ALS progresses, the goal of patient care often shifts from maximizing function to providing compassionate palliative care. The goal of palliative care is to achieve the best possible quality of life for patients and their families. Uncontrolled studies report some benefit from hospice care in improving the quality of life of patients with ALS. A retrospective analysis of hospice chart data showed that 94% of patients with motor neuron disease were judged to be ''peaceful and settled'' at death in hospice. Too often, end-of-life discussions are started only when patients are ill and have little time to discuss their preferences. Advance care directives can serve as a means for patients to communicate their wishes about end-of-life care with health care professionals, family members, and friends. Patients with ALS have been known to change their preferences for cardiopulmonary resuscitation and ventilator care for respiratory failure. The physician should address the risks and benefits of treatments on a regular basis in an unbiased way and understand that the patient's choices could change as the disease progresses.
After Death
The death of a person has a lasting effect on the family, and only 22% of respondents in one study coped well in later life. Nearly all caregivers incurred substantial financial hardship, and selfdefined burnout was reported in 82% of caregivers. Grief and bereavement support should be an integral part of the ALS care. Measures such as a letter of condolence, an offer to provide a professional with whom loved ones could talk, and appropriate referrals to psychologists or psychiatrists when required are very important.
Known Disease-Modifying Therapies
Only one drug has ever been shown to prolong survival in patients with ALS: riluzole. Riluzole, a benzothiazole, affects neurons by three mechanisms: (1) inhibiting excitatory amino acid release, (2) inhibiting events after stimulation of excitatory amino acid receptors, and (3) two randomized double-blind placebocontrolled trials in patients with ALS have demonstrated that riluzole can extend survival and/or time to tracheostomy. After 18 months, the relative risk of death or tracheostomy with riluzole 100 mg/d was reduced by 21%. On average, patients in these studies lived without tracheostomy 2 to 3 months longer than patients taking placebo. Although riluzole slowed the rate of deterioration in muscle strength in the first trial, this was not confirmed in the second larger trial. Riluzole had no effect on any other functional or secondary variable. Gastrointestinal effects, anorexia, asthenia, circumoral paresthesia, and dizziness were reported more frequently with riluzole than placebo. Elevated alanine aminotransferase levels were observed in 10.6% versus 3.8% of patients treated with riluzole 100 mg/d versus placebo, leading to treatment withdrawal in 3.8% versus 2.1% of patients. Monitoring of serum transaminases is recommended monthly for the first 3 months of therapy, every 3 months for the remainder of the first year of therapy, and periodically thereafter. Riluzole might have limited effect in the advanced stages of the disease, and it is not clear if and when treatment with riluzole should be stopped. Nonetheless, riluzole is an important breakthrough as it is the only medication that prolongs survival in ALS.
Noninvasive ventilation is another proven disease-modifying therapy (Heiman-Patterson and Miller, 2006) . Numerous studies of different design have confirmed this. A randomized controlled trial of noninvasive positive pressure ventilation (NIPPV) versus standard care showed a median survival benefit of 205 days and an improved quality of life associated with NIPPV. Early signs and symptoms of respiratory muscle weakness are subtle and include dyspnea on exertion, supine dyspnea, marked fatigue, sleep disturbance (frequent nocturnal awakenings, excessive daytime sleepiness), and morning headaches. The AAN ALS practice parameter recommends that noninvasive ventilation should be considered if the patient is symptomatic or the vital capacity either sitting or supine is less than 50% of predicted (Miller et al, 1999) . FVC is insensitive in patients with bulbar dysfunction or pseudobulbar palsy with apraxia of facial muscles. Sniff nasal pressure of 40 cm of H 2 O or less may be a more sensitive indicator of respiratory failure. Nocturnal oximetry is also sometimes useful in evaluating nocturnal hypoventilation (O 2 saturation of less than 90% for greater than 5% of the time asleep). Noninvasive ventilation is usually provided by BiPAP, as opposed to continuous positive pressure ventilation. Patients and families often consider noninvasive ventilation more desirable than invasive ventilatory support with tracheostomy. At some centers in the United States more than 50% of patients with ventilatory impairment use noninvasive ventilation. A trial of diaphragmatic pacing is underway, and it will be interesting to see how this interacts with the use of noninvasive ventilation.
Optimization of nutritional status appears to be a disease-modifying therapy. Rapid weight loss and low body mass index (less than 18.5) are associated with poor survival. Reasons for malnutrition and weight loss in ALS include dysphagia, upper limb weakness making patients depend on others to cut their food and feed them, loss of appetite secondary to depression or constipation, and increased caloric utilization. Monitoring weight at each visit is a simple and useful screen for malnutrition. Gastrostomy tube placement is specifically indicated when patients with ALS have symptomatic dysphagia with weight loss resulting from insufficient calorie intake, dehydration, or ending meals prematurely because of choking on food. The timing of percutaneous endoscopic gastrojejunostomy (PEG) should also be considered in relation to pulmonary status and should not be placed in the preterminal phase of the disease. To minimize risks, evidence suggests that PEG should be placed before vital capacity falls below 50% of predicted (Andersen et al, 2007; Miller et al, 1999; Radunović et al, 2007) . Two studies suggest that use of a gastrostomy tube may prolong survival. Patients with gastrostomy tubes lived on average 1 to 4 months longer than patients who refused or who were deemed ineligible for placement. The survival advantage was greatest in patients with vital capacity greater than 50% at the time of gastrostomy tube insertion.
Lastly, there is exercise. Muscle weakness is common in people with ALS. Inactivity can lead to further deconditioning and disuse weakness, joint stiffness and contractures, and pain. Therapeutic exercises can help maintain flexibility and relieve discomfort. Two recent randomized controlled trials, one evaluating the effect of twicedaily endurance exercise and the other evaluating the effect of twice-daily resistance exercise, showed some benefit in terms of rate of decline of the ALS Functional Rating Scale at 3 months. However, these studies were small and additional research in the area is needed (Dalbello-Haas et al, 2008) .
Symptomatic Therapies
Symptomatic therapies currently play an integral part in management of patients with ALS. In recent years a number of options have become available for managing many of the troublesome symptoms experienced by patients with ALS. Effective management of these symptoms may maximize function, improve quality of life, and increase independence. Unfortunately, controlled studies evaluating the efficacy of symptomatic therapies in ALS are generally lacking. As a result, the recommendations below are largely based on small recent studies, experience in other neurologic disorders, and recently published practice guidelines. Common symptoms of ALS, their possible etiology, available therapies based on AAN practice parameters, the European ALS Consortium's Task Force Recommendations, and evidence-based medicine are summarized in Table 4 -5.
Spasticity and cramps can cause pain and impair function in patients with ALS. Unproven but currently employed options for management include stretching exercises, hydrotherapy in heated pools, and the drugs baclofen (30 mg to 80 mg daily), tizanidine (2 mg to 24 mg daily), gabapentin (900 mg to 2400 mg daily), dantrolene (25 mg to 100 mg daily), tetrazepam (100 mg to 200 mg daily), and diazepam (10 mg to 30 mg daily). A small open-label pilot study recently showed that treatment with levetiracetam (1500 mg twice a day) was associated with reduction in phasic but not tonic spasticity and in cramp frequency and severity in patients with motor neuron diseases, including ALS; a randomized trial is necessary to confirm these findings. In another recent article, intrathecal baclofen in two ALS patients with intractable spasticity was more effective than oral medication; in practice, intrathecal baclofen is typically reserved for patients who are refractory to other therapies.
Sialorrhea causes significant social stress to the patients. Poor handling of saliva appears to be the major cause of sialorrhea in ALS. Amitriptyline is widely used in patients with ALS, especially when there is comorbid " ALS UPDATE continued on next page sleep disturbance, depression, or pseudobulbar affect, but it has not been studied in controlled trials for this purpose. Other unproven pharmacologic agents that are often employed include glycopyrrolate, transdermal hyoscine, benztropine, trihexyphenidyl, and atropine. Suction machines, manually assisted coughing techniques, and mechanical insufflation-exsufflation devices are also effective in clearing excess mucus from airway. Two additional approaches may be considered when medical treatments fail. External beam radiation (3 Gy to 30 Gy) to a single parotid gland or injection of botulinum toxin into the parotid glands may be effective in reducing sialorrhea. For thick mucus secretions, addition of a beta-blocker, such as propanolol (Inderal) or metoprolol (Toprol), anecdotally appears to benefit patients with ALS. Speech impairment can be frustrating both for the communicator and the listener. Augmentative and alternative communication strategies refer to a system used to augment existing speech or serve as an alternative when there is no speech. Use of voice amplifiers, writing boards, communications boards, signaling systems (eg, hand signals, facial expressions, eye movements, gestures, touch, and body language) are simple strategies that permit continuing human contact. High-technology communication devices that offer text to speech or prestored messages are available. Some of these systems can be linked to household devices so that a person with ALS can independently control the television, telephone, lights, etc. An exciting new technology called brain-computer interface may soon allow patients to interface with a computer independent of muscle movement.
Other assistive devices are often employed to maximize independence as arm and leg strength deteriorates. These range from walking aids to transfer devices to home adaptations such as ramps. Caregivers should be instructed in proper body mechanics and safe and effective transferring techniques. Mobility function and assistive Pseudobulbar affect (also called involuntary emotional expression disorder) is characterized by involuntary laughing and/or crying that is not congruent with mood. Approximately 50% of patients with ALS experience this over the course of the disease. It can be distressing and even socially disabling. Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) are often used to treat this condition. A combination of dextromethorphan and quinidine has been shown to be beneficial in preliminary studies, with a definitive trial currently underway.
Anxiety, depression, pain, constipation, and dyspnea are other symptoms that are commonly experienced by patients with ALS over the course of their disease. Again, no trials are available to guide management. Many clinicians utilize SSRIs and/or benzodiazepines for anxiety and SSRIs or tricyclics for depression. Pain is usually in the joints, and nonsteroidal antiinflammatory drugs (NSAIDS) and exercise are often helpful in alleviating this. A good bowel regimen consists of fiber and a stool softener, and if they fail, laxatives and enemas. Morphine and lorazepam or valium are useful for controlling dyspnea and the anxiety associated with it and should be titrated liberally (Case 4-1, Part 2).
ALS CLINICAL TRIALS
Gains in understanding ALS pathophysiology, coupled with high-throughput drug screening and the emergence of new technologies such as gene and stem cell therapies have resulted in an impressive ALS therapeutic pipeline. More than 31 different compounds have been tested in phase 2 and 3 clinical trials over the last 15 years (Table 4-6). A detailed list of potential candidates in ALS can be found in recent reviews (Bedlack et al, 2007; Benatar, 2007; Traynor et al, 2006) . We will briefly review some of the drugs used in current and upcoming clinical trials in ALS (Table 4-7) . Information about the latest open trials in ALS is also available for physicians and patients at www.clinicaltrials.gov.
Arimoclomol
Arimoclomol acts as a potent coinducer of molecular chaperone or heat shock gene expression. Decreased availability of heat shock proteins (HSPs) has been shown to precede degeneration in motor neurons in SOD1 transgenic mice, and up-regulating HSPs prolongs the viability of motor neurons. Arimoclomol slowed development of motor symptoms and prolonged survival in the transgenic mouse model of ALS (Kieran et al, 2004) . In a phase 2a, double-blind, placebo-controlled, doseranging safety and pharmacokinetics study, arimoclomol at dosages up to 300 mg/d were well-tolerated and safe in ALS (Cudkowicz et al, 2008) .
Ceftriaxone
This cephalosporin antibiotic increases EAAT2 promoter activation and subsequent EAAT2 activity in rodent brains and prolongs survival in FALS1 mice (Rothstein et al, 2005) . Ceftriaxone also protects motor neurons in culture from excitotoxic cell death and has antioxidant and antiapoptotic activity. An innovative phase 1-3 adaptive design pharmacokinetic, safety, and efficacy study is underway in patients with ALS.
MCI-186
MCI-186 (3-methyl-1-phenyl-2-pyrazolin-5-one), also called edavarone, is a small 
Case 4-1, Part 2
On the patient's first follow-up visit, the neurologist gave the diagnosis to the patient with his wife present. The progressive nature of the disease was explained. Variability in progression was stressed, as were the many options available to him in the clinic, including some research trials. Riluzole was provided as an option and started after normal liver transaminases were obtained. Transaminases were checked monthly for the first 3 months, then every 3 months afterward. The patient was seen by the entire multidisciplinary team. The occupational therapist gave him devices to assist in opening jars, writing, and dressing. The physical therapist taught him home exercises and provided for an ankle-foot orthotic. The nutritionist taught him the importance of good nutrition and proper caloric intake, and a calorie count was initiated. The neuropsychologist screened him for depression, anxiety, and cognitive and behavioral disturbances and found only pseudobulbar affect. The social worker gave him written educational information about ALS, including online resources and the location of support groups in his area. It was pointed out that it may be helpful for his wife and children to attend some of the groups. The social worker also explained the process of applying for disability, including the unique benefits available to him as a veteran, and helped him apply for a handicapped parking permit. The respiratory therapist noted his mildly reduced FVC, showed him breath-stacking and hyperinflation techniques, and discussed smoking cessation. Speech therapy staff introduced themselves but found no need for intervention at that visit. The neurologist and research nurse discussed research options with the patient, and he decided to participate in a therapeutic trial for pseudobulbar affect. Follow-up visits were scheduled every 3 months.
Over time, the patient's strength deteriorated, but he remained comfortable. His pseudobulbar affect was controlled by study medication. He obtained 100% service-connected disability through the Veterans Administration medical center. He created a health care power of attorney and living will. He eventually developed some subtle new problems with executive function, noticed by the neuropsychologist. As a result, an even greater emphasis was placed on including his family in all discussions and sending them home with resources to supplement any discussions about options for his increasing number of care-related issues. As his weakness worsened, he progressed from a cane to a walker to a power wheelchair. As his hands and arms became weaker, he was given wrist splints; later his wife was taught optimal techniques for helping him with his activities of daily living. Eventually a home health aide was enlisted to assist with these and provide his wife some respite. As his FVC fell to around 50% of predicted, he began to notice dyspnea with transfers and lying flat. BiPAP was instituted with resolution of symptoms. Although his weight had been stable, his falling FVC prompted referral for PEG insertion. Gradually he transitioned to taking most of his nutrition through the PEG. He acquired a speech-generating device; over time he learned to control this in different ways, eventually with his eye movements. As his FVC fell well below 50%, hospice was enlisted. Morphine in the form of oral drops was used for his air hunger and pain and diazepam for anxiety as needed. He died comfortably at home in his sleep 2 years from his ALS diagnosis. Bereavement counseling was provided for his family.
Comment. This case illustrates the progress that has been made in the care of patients with ALS and their families. This patient and his family received physical and emotional support from their multidisciplinary ALS clinic. Medications were used to successfully treat troublesome symptoms of pseudobulbar affect, air hunger, pain, and anxiety. Equipment was provided that maximized his independence. The multidisciplinary team, BiPAP, and PEG all contributed to a better quality of life for this patient. Riluzole and exercise were used and may have slowed his progression as well. Disease education was provided for the patient and his family at every step. When regular screening by the neuropsychologist detected early cognitive problems, the nature of the education provided was appropriately altered. He was well prepared for the later stages of his disease, and his desire for a natural death was respected. He was able to die comfortably at home with hospice near his family, and the family continued to receive support after his death.
" ALS UPDATE molecule that acts as a free radical scavenger, blocks mitochondrial transition pore, and up-regulates bcl-2 expression. In an open-label phase 2 study of 20 patients with ALS, IV administration of MCI-186 was safe and well tolerated. Markers of oxidative stress were favorably affected, and there was a suggestion of slowed disease progression as measured by the ALS Functional Rating Scale (Yoshino and Kimura, 2006) .
ONO-2506
ONO-2506 is an enantiomer of valproic acid that may restore normal astrocyte function after brain damage by preventing reactive astrocytosis by activating astrocytic -aminobutyric acid (GABA) A receptors and suppressing GABA transferase. This agent has additional antiglutamate and anti-inflammatory COX-2 inhibitor properties. A phase 2 study in humans has been completed, and a phase 3 study has begun.
KNS-760704
Pramipexole is a dopamine agonist used in Parkinson disease that can reduce oxidative stress in patients with ALS. In cell culture and animal studies, this enantiomer of pramipexole can block the mitochondrial transition pore and block caspase activation. Since it has less affinity for dopamine receptors than pramipexole, it should have fewer side effects. In FALS1 mice, R(+) pramipexole prolongs survival (Danzeisen et al, 2006) . A multipledosage phase 2 safety study in humans is underway.
Talampanel
This compound is a noncompetitive modulator of amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. It prolonged survival in FALS1 mice and was safe and well tolerated in a phase 2 study in patients with ALS. ALS Functional Rating Scale and Tufts Quantitative Neuromuscular Examination scores declined at a slower rate in a 9-month study of talampanel in 60 patients with ALS. A phase 2b study in humans is underway.
TRO19622
This compound is reported to inhibit the opening of the mitochondrial transition pore, act as a noncompetitive glutamate antagonist, and have antiapoptotic properties. It can maintain weight and motor function in FALS1 mice and prolong survival in models of other motor neuron diseases. It appears safe and well tolerated in a small preliminary study of patients with ALS (Abitbol et al, 2006) . A phase 2 study is under consideration.
Lithium
Chronic lithium treatment up-regulates cell survival molecules (eg, Bcl-2, cyclic AMP-responsive element binding protein, brain-derived neurotrophic factor, Grp 78, Hsp 70, and beta-catenin), while down-regulating proapoptotic activities (eg, excitotoxicity, p53, Bax, caspase, cytochrome c release, -amyloid peptide production, and tau hyperphosphorylation) (Chuang, 2005) , thus preventing or even reversing neuronal cell death and neurogenesis retardation. Recently, administration of lithium to G93A SOD1 mice prolonged survival compared with placebo (Fornai et al, 2008) . Lithium delayed cell death within lamina IX of the spinal cord and cranial motor neurons, while it increased the number of lamina VII Renshaw-like neurons. Lithium also decreased reactive gliosis, rescued spinal cord mitochondria, and produced a marked regression of -synuclein, ubiquitin, and SOD1 aggregates. In a small pilot study performed in Italy, participants treated with lithium demonstrated a slower rate of functional decline as measured by the Revised ALS Functional Rating Scale (Fornai et al, 2008) . In addition, no fatalities occurred in the lithium group after 15 months, while 29% of participants taking only riluzole died. Many methodologic problems with this small pilot study limited its conclusions. A multicenter phase 2 trial is currently planned to replicate the results of the Italian study.
Pioglitazone
Peroxisome proliferator-activated receptors (PPARs) are involved in the inflammatory process. Agonists of PPAR-, PPAR-, and PPAR-show anti-inflammatory effects both in vitro and in vivo. Orally administered pioglitazone, a PPAR-agonist, revealed improved muscle strength and body weight and exhibited a delayed disease onset and significantly longer survival of G93A mice as compared to the untreated control group.
Gene Therapy Intraventricular administration of antisense oligonucleotide to SOD1 significantly slowed disease progression in the mouse model of ALS caused by mutation in SOD1. Both SOD1 protein and messenger RNA levels were reduced throughout the brain and spinal cord (Smith et al, 2006; Wang et al, 2008) . A human trial of antisense oligonucleotide is being planned for people with SOD1-mediated FALS. Vascular endothelial growth factor (VEGF) is a cytokine that has protective function via angiogenic neurotrophic, gliotrophic, and antiapoptotic activities. Intracerebroventricular delivery of recombinant VEGF in the G93A rat model of ALS delays onset of paralysis by 17 days (Ryu and Ferrante, 2007) . The neuronal expression of a transgene expressing the VEGF receptor prolonged survival of G93A ALS mice. VEGF gene therapy may be used in clinical trials in the near future.
Vaccine Therapy A recent study showed that immunization strategies using repeated injections of bacterially purified recombinant SOD1 mutant protein before symptom onset at 6 months of age were effective in delaying disease onset and extending the life span of G37R SOD1 mice (Urushitani et al, 2007) .
Stem Cell Therapy
Stem cells are the only therapy that offers the potential for restoring lost function. An impressive display of the potential for this type of therapy was provided in 2006. Rats were exposed to Sindbis virus, which killed motor neurons, resulting in paralysis. Genetically modified embryonic stem cells were then injected into their lumbar cord, along with an antimyelin repulsion factor and PDE4 inhibitor. Systemic cyclosporine A was administered, and glial cell line-derived neurotropic factorsecreting cells were placed in a target muscle. A few months after transplants, the animals regained strength and some walked again (Deshpande et al, 2006) . In another recent study, embryonic neural stem cells transplanted into the spinal cord of FALS1 rats differentiated into neurons, formed synaptic contacts, released growth factors, and extended the life span of the animals. Mazzini and colleagues (2008) showed that intraspinal cord implantation of autologous mesenchymal stem cells in patients with ALS shows a significant slowing of linear decline of the FVC 36 months after the mesenchymal stem cell transplantation; unfortunately, lack of a control group makes this data very difficult to interpret. Most recently of all, investigators were able to convert skin cells from an elderly patient with ALS into stem cells and then differentiate them into motor neurons (Dimos and colleagues, 2008) . This breakthrough could yield a noncontroversial source of stem cells for use in future trials, as well as a new tissue culture model for studying ALS mechanisms and for screening therapeutic candidates. made to optimize the pathway by which potential ALS therapeutics are tested. With regard to the preclinical paradigm as described above, ideas for new therapies often come from observations made in FALS1 animal models. However, patients with FALS1 typically account for less than 5% of our trial populations; some trials even exclude FALS1 patients altogether. As has been pointed out earlier, important differences may occur in the pathophysiology of FALS1 and SALS. Another issue is the timing of the drug treatment in SOD1 mice. Presymptomatic treatment may not be ideal with respect to sporadic ALS since there is an average delay of 12 to 15 months from symptom onset to diagnosis in patients with ALS. The lack of concordance between FALS1 animal results and human ALS trial results seen with gabapentin, celecoxib, and creatine could be explained by these differences in disease pathophysiology, in the timing of drug delivery, or by other factors. Standardization of FALS1 animal copy number, genetic background, gender, and timing of therapy is now appropriately getting more attention.
Potential Development Issues
The design and conduct of ALS clinical trials themselves is coming under greater scrutiny as well. The randomized, double-blind, placebocontrolled trial remains the criterion standard for establishing efficacy. However, these trials are expensive, timeconsuming, and require large numbers of patients. Creative designs for phase 2 studies, including selection and futility designs and the use of historical controls are now allowing faster rejection of less-promising therapeutic candidates, which maximizes the limited monetary and patient resources available to ALS researchers. Selecting the primary outcome measure for an ALS trial remains a major challenge. Survival is the criterion standard, but defining death is complex in ALS, especially with the advent of life-extending measures such as NIPPV. Based on its simplicity and practicality, the Revised ALS Functional Rating Scale has gained wide acceptance for use as a primary outcome measure in clinical trials. Many drugs have been taken through clinical trial without knowledge of whether the doses being studied actually affected their proposed mechanisms in humans with ALS; recent examples in which the doses of study medications may have been too low include creatine and celecoxib. Several clinical trials in ALS have tested the maximally tolerated dosages of test medication, which may increase the chance of intolerable side effects or worsening of functional measures in people with ALS, as seen with topiramate and minocycline. Finally, enrollment in ALS clinical trials has been surprisingly poor. Data from two major academic centers suggest that only about 8% of people with ALS in these clinics are enrolled in a clinical trial; on average, in both Europe and the North America, two people with ALS per trial site per month are enrolled in a clinical trial . A study of enrollment variability across ALS trials suggests that the enrollment rate is not affected by trial design factors, such as presence of a placebo group or invasiveness of the outcome measure being studied. Patient factors, such as desire to utilize alternative or off-label treatments, and physician factors, such as enthusiasm over the intervention being studied and willingness to proactively educate patients about alternative and off-label therapies, appear to be larger determinants of enrollment and are potentially modifiable. " ALS UPDATE and disease management over the past few years. The very concept of ALS has changed from a single disease specific for motor neurons to a group of similar diseases in which other populations of neural cells are affected in clinically important ways. The initiating events are now known for many subtypes of FALS, and hints about genetic and environmental initiators for SALS are being uncovered. Downstream mechanistic events are starting to come together for FALS1. Many, but not all of these, appear to occur in SALS. The diagnosis of most ALS subtypes remains slow and cumbersome, but we may be on the cusp of a CSF test for ALS that has the potential to speed diagnosis and in doing so increase optimism for finding new disease-modifying therapies. In the meantime, riluzole, multidisciplinary clinics, noninvasive ventilation, and optimal nutrition prolong survival and improve the quality of life for patients with ALS. Many new options are available for managing symptoms in patients with ALS. The pipeline of potential therapeutics has never been richer, and improvements in our current ALS drug screening and clinical trial programs will allow us to work through this pipeline more efficiently than ever before.
CONCLUSIONS AND NEW DIRECTIONS
